International registry for very rare childhood tumors
Official title: The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.
Run by Azienda Ospedaliera di Padova · NCT07072143 · Data updated 2026-11-12
This project will collect detailed medical information to see how clinical and biological features affect outcomes in children and adolescents with very rare tumors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Years to 18 Years |
| Sex | All |
| Enrollment | 6250 (estimated) |
| Sponsor | Azienda Ospedaliera di Padova Academic / other |
| Locations | 1 site (Padova, Italy) |
| Status | Recruiting |
| Started | January 25, 2025 |
| Main results expected | January 6, 2049 |
| Study ends | June 6, 2049 |
| Registry record updated | July 18, 2025 |
| Trial ID | NCT07072143 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and adolescents aged 0–18 with a primary or relapsed very rare tumor (typically incidence <2 per million per year) who are diagnosed or treated at a participating center and who provide written informed consent are eligible.
✕Probably not a fit
Patients older than 18, those with common tumor types, those not treated at participating centers, or those who do not provide consent are unlikely to gain direct benefits from this observational data collection and will not receive experimental therapies through the project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The PARTNER initiative is a prospective, observational international registry that gathers epidemiological, clinical, biological, radiological, and treatment data on children and adolescents with very rare tumors. It enrolls patients aged 0–18 with primary or relapsed malignancies that are very rare in childhood and requires written informed consent from patients or guardians. The study does not assign any experimental treatments and is run as a non-profit effort led by Padua University Hospital with collaborating European centers in the EXPeRT network. By pooling standardized data across countries, the project aims to improve diagnostic criteria and inform future treatment recommendations for these understudied tumor types.
Why it matters
Potential benefit: If successful, the registry could improve future diagnosis and treatment recommendations and ultimately help improve outcomes for children with very rare tumors.
How similar studies have gone: Previous international registries and collaborative networks have produced modest gains in knowledge and care for some rare pediatric cancers, so this project builds on prior collaborative experience rather than introducing an untested concept.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center. * Written informed consent from the patient and/or the parent/legal guardian Exclusion Criteria: * Absence of Written informed consent from the patient and/or the parent/legal guardian
Where it's running
-
Pediatric Oncology Unit, University Hospital Padova [AOUP Azienda Ospedale Università Padova]
Padova, Italy, Italy Recruiting
Study contacts
- Principal investigator: Gianni Bisogno, MD — Azienda Ospedale Università Padova - Italy
- Study coordinator: Gianni Bisogno, MD
- Email: gianni.bisogno@unipd.it
- Phone: 0039 0498211481
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Partial pleurectomy to relieve symptoms from unresectable pleural mesothelioma.
The team will try a limited partial pleurectomy and decortication to reduce chest symptoms and improve quality of life for people with epithelioid pleural mesothelioma that cannot be completely removed.
-
Treatment with Sacituzumab Govitecan for Mesothelioma
This study tests if a new treatment called sacituzumab govitecan can help people with mesothelioma who have already tried other therapies feel better and manage their disease.
-
Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy
This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.
-
Registry for rare lung tumors and DICER1-related conditions
This study is collecting information about rare lung tumors in children, like pleuropulmonary blastoma, to help doctors understand how these conditions develop and how to treat them better.
-
Structured swallowing exercises for nasopharyngeal cancer patients
This trial tests whether a structured swallowing exercise program improves swallowing and quality of life more than conventional swallowing exercises in adults with nasopharyngeal carcinoma.
-
Dynamic risk prediction for severe blood cell suppression in nasopharyngeal cancer
This study tests a dynamic risk model to see if it can predict grade 3 or higher anemia, low platelets, or low white blood cells during systemic therapy for adults with nasopharyngeal cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.